The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
miRNA-based biomarkers, therapies, and resistance in Cancer
Open accessAbstract
MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10 retracted
Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., Xu, P., Sun, G., Xu, J., Lv, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0935-5 · Cited by 842
RetractedPichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
RetractedYan, S., Tang, Z., Chen, K., Liu, Y., Yu, G., Chen, Q., Dang, H., Chen, F., Ling, J., Zhu, L., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0853-9 · Cited by 111
RetractedJiang, H., Huang, G., Zhao, N., Zhang, T., Jiang, M., He, Y., Zhou, X., & Jiang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0846-8 · Cited by 79
RetractedChen, S., Chen, X., Shan, T., Ma, J., Lin, W., Li, W., & Kang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22555 · Cited by 62
RetractedZhou, Z., Zhang, H., Deng, T., Ning, T., Liu, R., Liu, D., Bai, M., Ying, G., & Ba, Y. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.006 · Cited by 59
RetractedLi, F., Wang, F., Zhu, C., Wei, Q., Zhang, T., & Zhou, Y. L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157805 · Cited by 47
RetractedPichiorri, F., Suh, S.-S., Rocci, A., Luca, L. D., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.007 · Cited by 29
RetractedFeng, S.-D., Mao, Z., Liu, C., Nie, Y., Sun, B., Guo, M., & Su, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s149632 · Cited by 26
RetractedSong, A., Zhao, L., Wang, Y., He, D., & Li, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28812 · Cited by 15
Retracted
Cited by
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Metadata
- Authors
- He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., Xie, H., Peng, X., Yin, W., Tao, Y., & Wang, X.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 16
- Issue
- 14
- Pages
- 2628-2647
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W3044903507
- Cited by
- 625
- References
- 218
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miRNA-based biomarkers, therapies, and resistance in Cancer. https://app.cochat.ai/papers/10.7150/ijbs.47203
- The paper
- He, B., Zhao, Z., Cai, Q., Zhang, Y., Zhang, P., Shi, S., Xie, H., Peng, X., Yin, W., Tao, Y., & Wang, X. (2020). miRNA-based biomarkers, therapies, and resistance in Cancer. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.47203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.